Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Swine-flu research increases stock market visibility of Aethlon Medical

Aethlon Medical : 11 September, 2009  (Company News)
RedChip predicts share price increase at Aethlon Medical due to its work on blood filtering technology leading to valuable swine-flu related information
RedChip Visibility has issued a first quarter research update on Aethlon Medical, a company developing a therapeutic device to treat acute and chronic viral infections, biological warfare pathogens, and other conditions by filtering virus particles and immunosuppressive agents from the blood.

David Webber, RedChip Research Analyst, reported: 'Over the summer, Aethlon advanced its programs in the treatment of hemorrhagic fever viruses, which are potential bio-terror agents, and swine flu, which remains a source of serious health concern.

The Company also continued to prepare an amendment of its application to the Food & Drug Administration for permission to test the Hemopurifier in the US in chronic hepatitis C patients, advanced other non-core programs, raised enough funds to meet operational needs, and reportedly continued discussions with potential partners.

We believe this progress, which could generate preliminary swine flu data by year's end, helps make the Company more attractive to potential partners.'

Webber continued: 'We rate AEMD a 'Speculative Buy' with a 12-month price target of $1.00 per share. We expect the stock to be driven by incremental validation of the device's potential in the form of partnerships and/or clinical data.'
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo